The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Gary Remington

Department of Psychiatry

University of Toronto

Toronto

Canada

[email]@camh.net

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Psychiatry, University of Toronto, Toronto, Canada. 2001 - 2012
  • University of Toronto, Toronto, Ontario, Canada. 2011
  • Centre for Addiction and Mental Health, Clarke Division, Toronto, Ontario, Canada. 2001 - 2006
  • Department of Psychiatry, University of Toronto, Centre for Addiction and Mental Health, Toronto, Ont. 2003 - 2005
  • Medical Assessment Program for Schizophrenia, Centre for Addiction and Mental Health, 250 College Street, Totonto, Canada. 2005

References

  1. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. Remington, G., Kapur, S., Foussias, G., Agid, O., Mann, S., Borlido, C., Richards, S., Javaid, N. J. Clin. Psychopharmacol (2012) [Pubmed]
  2. Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment. Remington, G., Agid, O., Foussias, G. Expert. Rev. Neurother (2011) [Pubmed]
  3. Progress in defining optimal treatment outcome in schizophrenia. Remington, G., Foussias, G., Agid, O. CNS. Drugs (2010) [Pubmed]
  4. Alterations of dopamine and serotonin transmission in schizophrenia. Remington, G. Prog. Brain Res. (2008) [Pubmed]
  5. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Remington, G. Curr. Opin. Psychiatry (2007) [Pubmed]
  6. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Remington, G., Kwon, J., Collins, A., Laporte, D., Mann, S., Christensen, B. Schizophr. Res. (2007) [Pubmed]
  7. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Remington, G., Mamo, D., Labelle, A., Reiss, J., Shammi, C., Mannaert, E., Mann, S., Kapur, S. Am. J. Psychiatry (2006) [Pubmed]
  8. The crossover approach to switching antipsychotics: what is the evidence?. Remington, G., Chue, P., Stip, E., Kopala, L., Girard, T., Christensen, B. Schizophr. Res. (2005) [Pubmed]
  9. Rational pharmacotherapy in early psychosis. Remington, G. Br. J. Psychiatry. Suppl (2005) [Pubmed]
  10. Augmentation strategies in clozapine-resistant schizophrenia. Remington, G., Saha, A., Chong, S.A., Shammi, C. CNS. Drugs (2005) [Pubmed]
  11. The use of pharmacotherapy in the prodrome of schizophrenia. Remington, G., Shammi, C. CNS. Spectr (2004) [Pubmed]
  12. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. Remington, G. J. Psychiatry. Neurosci (2003) [Pubmed]
  13. 'Atypical' antipsychotics: where does ziprasidone fit?. Remington, G. Expert. Rev. Neurother (2002) [Pubmed]
  14. Antipsychotic dosing patterns for schizophrenia in three treatment settings. Remington, G., Shammi, C.M., Sethna, R., Lawrence, R. Psychiatr. Serv (2001) [Pubmed]
  15. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. Remington, G., Sloman, L., Konstantareas, M., Parker, K., Gow, R. J. Clin. Psychopharmacol (2001) [Pubmed]
  16. SB-277011 GlaxoSmithKline. Remington, G., Kapur, S. Curr. Opin. Investig. Drugs (2001) [Pubmed]
 
WikiGenes - Universities